Fusion Antibodies plc (FAB.L)

GBp 6.6

(-2.94%)

Market Cap (In GBp)

6.33 Million

Revenue (In GBp)

1.13 Million

Net Income (In GBp)

-2.22 Million

Avg. Volume

1.07 Million

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.8-8.5
PE
-
EPS
-
Beta Value
0.458
ISIN
GB00BDQZGK16
CUSIP
G3708Z104
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Adrian Robert Kinkaid Ph.D.
Employee Count
-
Website
https://www.fusionantibodies.com
Ipo Date
2017-12-18
Details
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.